Navigation Links
Evidence against use of Beta blockers as first choice in the treatment of primary hypertension

Beta blockers have been used widely in the treatment of hypertension and are still recommended as first-line drugs in hypertension guidelines. Moreover, after myocardial infarction and in patients with heart failure, treatment // with beta blockers prevents re-infarction, hospitalisation for heart failure, and premature death. However, a preliminary analysis has shown that atenolol is not very effective in hypertension.

A recent study, published in the October-November issue of The Lancet, was conducted with the aim to substantially enlarge previous data on atenolol and analyse the effect of different beta blockers on stroke, myocardial infarction, and mortality of all causes .

For the study, the Cochrane Library and PubMed were searched for beta blocker treatment in patients with primary hypertension. Data were then entered into the Cochrane Collaboration Review Manager package and were summarised in meta-analyses. 13 randomised controlled trials were included in a meta-analysis comparing treatment with beta blockers with other antihypertensive drugs. Seven studies were included in a comparison of beta blockers and placebo or no treatment..

Results obtained showed that the relative risk of stroke was 16% higher for beta blockers than for other drugs. There was no difference for myocardial infarction. When the effect of beta blockers was compared with that of placebo or no treatment, the relative risk of stroke was reduced by 19% for all beta blockers, about half that expected from previous hypertension trials. There was no difference for myocardial infarction or mortality.

The authors conclude that in comparison with other antihypertensive drugs, the effect of beta blockers is less than optimum, with a raised risk of stroke.

The authors suggest that beta blockers should not remain first choice in the treatment of primary hypertension and should not be used as reference drugs in future randomised controlled tr ials of hypertension.


'"/>




Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Evidence supporting H.pylori eradication
3. Evidences that Better Health Care Facility is Offered By Public Hospitals.
4. First Conclusive Evidence Linking Oral Bacteria To Premature Babies
5. Study Provides Evidence That Obesity Leads To A More Aggressive Ovarian Cancer
6. No Clear Evidence for Ultra-Low Cholesterol Targets?
7. Lack of Evidence on Treatment for Narrowed Kidney Arteries
8. Some Evidence Shows Chinese Herbal Medicine Helps Angina Patients
9. Strong Evidence Suggests Incidence Of Mating Of Ancestors With Neanderthals
10. Dermatologists Provide Unique Evidence of Possible Cause of Rare Skin Condition
11. Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ... agreement to be the preferred physical therapy provider for Derby City CrossFit, effective ... Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent ... test score performance for the 2015-16 school year across Wisconsin’s public schools, charter ... it highlights important patterns in student test score performance, the report’s limited analyses ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
Breaking Medicine Technology: